SSX2 and synovial sarcoma: Since synovial sarcoma exhibits genomic stability with few somatic mutations aside from the SS18-SSX translocation, the fusion oncoprotein SS18-SSX is considered the key oncogenic driver, disrupting differentiation through widespread epigenetic dysregulation [13,14,15].